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Vancomycin-resistant enterococci colonization in patients at Among intensive care unit patients with nosocomial in-
seven hemodialysis centers. fections that have been reported to the Centers for Dis-
Background. Vancomycin-resistant enterococci (VRE) are ease Control and Prevention’s (CDC) National Nosoco-increasing in prevalence at many institutions, and are often re-
mial Infections Surveillance (NNIS) system, the percentageported in dialysis patients. We studied the prevalence of and
of enterococcal isolates resistant to vancomycin increasedrisk factors for VRE at seven outpatient hemodialysis centers
(three in Baltimore, MD, USA, and four in Richmond, VA, from 0.5% in 1989 to 25.2% in 1999 [1, 2]. Because spon-
USA). taneous mutations that would result in vancomycin resis-
Methods. Rectal or stool cultures were performed on con-
tance have not been described in enterococci, this in-senting hemodialysis patients during December 1997 to April
crease is attributable to patient-to-patient transmission1998. Consenting patients were recultured during May to July
1998 (median 120 days later). Clinical and laboratory data and in healthcare settings and transmission of resistance
functional status (1 to 10 scale: 1, normal function; 9, home genes among previously susceptible enterococci. The
attendant, not totally disabled; 10, disabled, living at home) rapid spread of VRE is of concern because infectionswere recorded.
due to this organism remain difficult to treat, despiteResults. Of 478 cultures performed, 20 (4.2%) were positive
the recent availability of two new drugs, quinupristin-for VRE. Among the seven centers, the prevalence of VRE-
positive cultures varied from 1.0 to 7.9%. Independently sig- dalfopristin and linezolid, that are active against vanco-
nificant risk factors for a VRE-positive culture were a func- mycin-resistant strains. The primary risk factors for VRE
tional score of 9 to 10 (odds ratio 6.9, P 0.001), antimicrobial
are increasing severity of illness and receipt of antimicro-receipt within 90 days before culture (odds ratio 6.1, P 0.001),
bial agents, particularly vancomycin [3–5].and a history of injection drug use (odds ratio 5.4, P  0.004).
Conclusions. VRE-colonized patients were present at all Vancomycin resistance has been common in patients
seven participating centers, suggesting that careful infection- with end-stage renal disease (ESRD). One of the first
control precautions should be used at all centers to limit trans- reports of VRE was among renal failure patients in amission. In agreement with previous studies, VRE colonization
hospital in London (UK) [6]. ESRD patients comprisedwas more frequent in patients who had received antimicrobial
17 to 29% of VRE case-patients in three hospital-basedagents recently, underscoring the importance of judicious anti-
microbial use in limiting selection for this potential pathogen. studies [5, 7, 8]. The percentage of U.S. hemodialysis
centers reporting 1 patients infected or colonized with
VRE increased from 11% in 1995 to 34% in 1999 [9, 10].
Vancomycin-resistant enterococci (VRE) were first re- Additionally, strains of Staphylococcus aureus with re-
ported in the late 1980s and in the interim have spread duced susceptibility to vancomycin have recently been
rapidly in the United States and many other countries. reported [11, 12]; of six U.S. patients from whom these
strains were isolated, four had received chronic and one
acute dialysis [13].Key words: pathogen, bacterial infection, infection control, transmis-
sion of VRE, ESRD, epidemic, chronic hemodialysis. Because of the prominent role that ESRD patients
have played in the epidemic of vancomycin resistance,Received for publication January 30, 2001
it is important to understand the epidemiology of VREand in revised form May 7, 2001
Accepted for publication May 15, 2001 in this patient population so that preventive measures
can be taken. We report the results of a study of the 2001 by the International Society of Nephrology
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prevalence of, and risk factors for, VRE colonization tures were performed during December 1997 to April
among chronic hemodialysis patients at seven U.S. dial- 1998. Repeat cultures were performed during May to
ysis centers. July 1998 among patients who consented to a second
culture. Specimens were inoculated onto selective agar
plates containing 10g/mL of vancomycin; isolates grow-METHODS
ing on these plates were tested for vancomycin resistance
Study centers and patients using National Committee for Clinical Laboratory Stan-
Seven dialysis centers—three in Baltimore (MD, USA) dards methods (disk diffusion or the E-test) [15]. Isolates
and four in Richmond (VA, USA)—participated in this showing vancomycin resistance by these methods were
study. Centers were selected to represent both urban transported to the CDC, where the genus and species
and suburban outpatient dialysis facilities. All chronic were determined by standard biochemical tests, and those
dialysis patients 18 years of age at the participating found to be Enterococcus faecium or E. faecalis were
centers were eligible for enrollment in the study. The tested by the broth microdilution technique. Isolates with
study protocol was approved by the Institutional Review a vancomycin minimum inhibitory concentration of32
Board (IRB) at the Centers for Disease Control and g/mL were considered to be VRE [15]. The isolates
Prevention (CDC) and at all study sites. were typed by pulsed-field gel electrophoresis. Isolates
were considered to be indistinguishable or closely related
Design and data collection (that is, to have a common pattern) if they were isolated
This study was conducted during December 1997 to from patients at the same dialysis center and there were
June 1998 at the centers in Richmond and January to July 3 band fragment differences when compared with the
1998 at the centers in Baltimore (that is, study period). common (modal) type for that dialysis center [16].
Study personnel used standardized forms to abstract data
from clinical and administrative records. A baseline form Statistical analysis
was completed on all patients at initiation of the study. Since some patients were cultured twice, the number
An incident form was completed at each outpatient initi- of cultures performed was higher than the number of
ation of a course of intravenous antimicrobials or at hospi- patients cultured. Thus, VRE prevalence was determined
tal admission. Data from the incident form were used to both for patients (that is, the percentage of patients that
tabulate intravenous antimicrobial uses and hospitaliza- were VRE positive on either the first or second culture)
tions that occurred during 90 days before culture for VRE; and cultures (that is, the percentage of all cultures that
however, since these events were recorded only during
were positive).
the study period, their ascertainment was incomplete for
To study the influence of potential risk factors at the
cultures performed during the first 90 days of the study.
time of VRE culture more precisely, the VRE prevalenceThe baseline form contained data on demographics;
among cultures was used for risk factor analyses, that is,the presence of diabetes, human immunodeficiency virus
the unit of analysis was the culture rather than the pa-(HIV) infection, or injection drug use known to dialysis
tient. For univariate analyses, P values were calculatedcenter staff; smoking; vascular access type (catheter,
by the chi-squared or Fisher exact test for dichotomousgraft, or fistula; patients having both a catheter and graft
variables or the likelihood ratio test for heterogeneityor fistula were categorized as having a catheter); albumin
(determined by logistic regression) for categorical vari-level (the mean of two determinations); urea reduction
ables with3 levels. For continuous variables, univariateratio (the mean of two determinations); whether skin/
P values were calculated with the nonparametric Wil-clothing was clean versus visibly soiled; and functional
coxon test.status. At baseline, functional status, similar to the Kar-
A multivariate model was constructed using general-nofsky performance scale [14], was scored as follows:
ized estimating equations [17]. This technique produces1, normal function; 2, minor signs and symptoms, full
odds ratios similar to those produced by logistic regres-activity; 3, usual activities with effort; 4, independent,
sion, but accounts for the lack of independence of obser-most out-of-home activities; 5, independent, limited to
vations (that is, that some patients were cultured twice).home; 6, needs assistance with errands; 7, needs assis-
Using a forward stepwise algorithm, all potential risktance with meal preparation; 8, needs assistance with
factors were considered for inclusion in the model; how-bathing/dressing; 9, home attendant, not totally disabled;
ever, only factors that were independently statisticallyand 10, disabled, living at home.
significant (P  0.05) were retained in the final model.
Cultures All P values are two-tailed. All data analyses were per-
formed using SAS for Personal Computers (SAS Insti-Stool or rectal cultures, according to patient prefer-
ence, were performed on consenting patients. Initial cul- tute, Cary, NC, USA).
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Table 1. Comparison of hemodialysis patients cultured vs. not cultured for vancomycin-resistant enterococci (VRE) colonization in
Baltimore and Richmond, December 1997–July 1998
Cultured Not cultured
Factor (N346) (N454) P value
Age median 62.0 57.0 0.006
Race % white 23.5 23.8 0.92
Functional status median 3.0 3.0 0.33
Diabetes % 43.7 41.2 0.48
HIV infection % 3.2 6.6 0.029
Injection drug use % 6.6 11.4 0.027
Albumin median 3.8 3.8 0.99
Urea reduction ratio median 71.0 70.5 0.14
Received any intravenous antimicrobial during the study period % 27.8 37.7 0.0032
Received intravenous vancomycin during the study period % 17.6 26.2 0.0047
RESULTS 7 a third-generation cephalosporin, 5 a quinolone, 3 a
penicillin, and 3 another antimicrobial (total 59 sinceCharacteristics of dialysis centers and patients
some patients received 1 antimicrobial). VRE preva-Of the seven centers, five were freestanding and two
lence was 2.9% among patients who had received nowere hospital-affiliated; three were located in an inner
antimicrobials, 14.3% among those who had receivedcity and four were suburban. These units treated a total
only vancomycin, 9.1% among those who had receivedof 800 patients (range 73 to 169 patients per center).
only antimicrobials other than vancomycin, and 17.4%Of the 800 patients eligible for culture, 346 (43.2%)
among patients who had received both vancomycin andconsented and were cultured one to two times (216 were
other antimicrobials (Table 2).cultured once and 130 were cultured twice). Compared
The urea reduction ratio was significantly lower forwith patients who were not cultured, the cultured patients
patients with VRE positive versus negative cultureswere significantly older and less likely to be HIV-infected,
(median 66.5% vs. 71.0%, P  0.019). However, VREto have known injection drug use, to have received any
colonization was not related to age (median 58.4 yearsantimicrobial agents, and to have received vancomycin
for VRE positive vs. 62.6 years for VRE negative, P (Table 1). Cultured versus noncultured patients were
0.48) or albumin level (median 3.6 g/dL for VRE positivesimilar in race, functional status, presence of diabetes,
vs. 3.8 g/dL for VRE negative, P  0.13).albumin level, and urea reduction ratio.
The multivariate model included three independent
Prevalence of VRE by patient predictors of VRE colonization: (1) functional status
score 9 to 10 (odds ratio 6.9), (2) antimicrobial receiptAmong the 346 patients cultured, 20 (5.8%) were VRE
during the previous 90 days (odds ratio  6.1), and (3)positive on either the first or second culture. Among pa-
injection drug use (odds ratio  5.4; Table 3). Hospital-tients cultured twice, 121 were VRE negative both times,
ization during 90 days prior to culture had an odds ratioone was negative then positive, eight were positive then
of 2.3 and a P value of 0.12 if inserted into the model.negative, and none were positive on both cultures. The
median duration between cultures was 120 days.
Genetic typing of VRE isolates
Prevalence of VRE by culture and risk factor analysis Two of the facilities (Centers B and E) had only one
isolate, so an evaluation for clustering of genetic typesOf 478 cultures performed, 20 (4.2%) were positive
was not possible. There was no intrafacility clusteringfor VRE. VRE prevalence was not related to city (Rich-
of genetic types among the isolates from centers A (2mond vs. Baltimore), urban versus suburban center, or
hospital versus freestanding location (data not shown). isolates), C (3 isolates), D (2 isolates), or G (3 isolates).
VRE prevalence varied from 1.0 to 7.9% among the Among isolates from center F (8 isolates), three shared
seven dialysis centers, but the differences were not statis- a common type, while two shared a second common type,
tically significant (P  0.32; Table 2). VRE prevalence and the remaining three isolates were unrelated.
was higher (14%) among patients with functional status
scores of 9 to 10 than among those with lower scores.
DISCUSSIONOther variables significantly related to VRE prevalence
We report VRE prevalence and risk factors amongincluded known injection drug use, hospitalization, and
hemodialysis patients at seven U.S. dialysis centers. Over-antimicrobial receipt.
all, 5.8% of the patients were VRE positive on eitherAmong 59 patients who had received an antimicrobial
the first or second culture, and 4.2% of all cultures were90 days before culture, 37 had received vancomycin,
27 an aminoglycoside, 9 a first-generation cephalosporin, positive. When analyzed by culture, VRE prevalence
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Table 2. Potential risk factors for vancomycin-resistant enterococci (VRE) colonization among hemodialysis outpatients in
Baltimore and Richmond, December 1997–July 1998
No. of No. (%) Relative
Factor cultures VRE positive risk P value
Center
A 71 2 (2.8) 2.8
B 47 1 (2.1) 2.1
Ca 59 3 (5.1) 5.0
D 41 2 (4.9) 4.8
E 98 1 (1.0) Ref
Fa 101 8 (7.9) 7.8
G 59 3 (5.1) 5.0 0.32b
Gender
Female 209 8 (3.8) Ref
Male 267 12 (4.5) 1.2 0.72
Race
Black, other 370 14 (3.8) Ref
White 105 6 (5.7) 1.5 0.41
Functional status
1–2 207 7 (3.4) Ref
3–4 144 5 (3.5) Ref
5–6 30 1 (3.3) Ref
7–8 43 1 (2.3) Ref
9–10 43 6 (14.0) 4.2 0.0061
Diabetes
No 259 11 (4.2) Ref
Yes 209 9 (4.3) 1.0 1.0
Known injection drug use
No 448 16 (3.6) Ref
Yes 28 4 (14.3) 4.0 0.024
Known HIV infection
No 463 19 (4.1) Ref
Yes 13 1 (7.7) 1.9 0.43
Access
Catheter 79 5 (6.3) 2.4
Fistula 77 2 (2.6) Ref
Graft 314 12 (3.8) 1.5 0.59b
Hospitalizations in previous 90 days
0 418 14 (3.3) Ref
1 58 6 (10.3) 3.1 0.025
Receipt of intravenous antimicrobials in previous 90 days
None 417 12 (2.9) Ref
Any 59 8 (13.6) 4.7 0.0001
Receipt of intravenous antimicrobials in previous 90 days
None 417 12 (2.9) Ref
Vancomycin only 14 2 (14.3) 5.0 0.07
Other antimicrobials only 22 2 (9.1) 3.2 0.15
Both vancomycin and other antimicrobials 23 4 (17.4) 6.0 0.0068
Culture specimen
Rectal swab 92 2 (2.2) Ref
Stool 374 18 (4.8) 2.2 0.39
Ref denotes reference group (relative risk  1.0).
a Hospital-affiliated unit (other units are freestanding)
b P value for heterogeneity among the groups calculated by logistic regression
ranged from 1.0% to 7.9% among the centers, and all near New York City [19], 6.0% at the Vanderbilt Univer-
sity Medical Center [20], and 8.1% at Johns Hopkinscenters had at least one patient with a VRE positive
culture. Independent risk factors for VRE colonization University Hospital [21]. Using a highly sensitive broth
enrichment technique, VRE were found in 13.8% ofincluded functional status score, antimicrobial receipt,
and injection drug use. patients hospitalized on the renal service of the Univer-
sity Hospital in Belgium [22] and 14% of dialysis outpa-These results are similar to those found in a number of
previous studies that have examined VRE colonization tients at 29 dialysis centers in Belgium [23]. In a study
in which selective media were not used, possibly reducingamong dialysis patients. VRE prevalence was 9.5% at
the center affiliated with the University of Maryland the probability of isolating VRE, VRE was found in
2.4% of dialysis outpatients at the Veterans Administra-Hospital [18] (this center also was included in the cur-
rently reported study), 9% among 111 dialysis patients tion Hospital in Indianapolis [24].
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Table 3. Multivariate model, risk factors for vancomycin-resistant unrelated; these clusters may have resulted from trans-
enterococci (VRE) colonization among hemodialysis outpatients mission in center F or in a local hospital or other health-in Baltimore and Richmond, December 1997–July 1998
care facility. Overall, these results shed little light on
95% the risk of VRE transmission from patient-to-patient inAdjusted Confidence
outpatient hemodialysis centers.Variable odds risk interval P value
This study has a number of limitations. Patients atFunctional status score
only seven centers were studied. Only 42% of eligible1–8 Ref — —
9–10 6.9 2.3–20.9 0.0006 patients consented to be cultured. Comparing cultured
Receipt of any intravenous anti- versus noncultured patients, cultured patients were lessmicrobial in previous 90 days
likely to have injection drug use and to have receivedNo Ref — —
Yes 6.1 2.3–16.4 0.0003 intravenous antimicrobials; therefore, VRE may have
Injection drug use been even more common in noncultured than cultured
No Ref — —
patients. The small number (N  20) of VRE isolatesYes 5.4 1.7–17.0 0.004
limited our ability to evaluate risk factors and identify
clusters by genetic typing. Hospitalization and antimicro-
bial receipt during 90 days before culture were examinedThe functional status score previously has not been
as risk factors; since these events were recorded onlylinked to VRE prevalence. However, functional status
once the study started, their ascertainment was incom-is a plausible risk factor since various manifestations of
plete for cultures performed during the first 90 days ofseverity of illness are known to be associated with VRE
the study. However, this limitation would be expected[4, 5, 7, 8]. An association between injection drug use
to make it less likely to find a statistically significantand VRE may have occurred because patients who abuse
result, and therefore hospitalization and antimicrobialdrugs may require more antimicrobials and hospitaliza-
receipt would be expected to show a stronger associationtions.
with VRE colonization had more complete data beenSome studies have found that vancomycin receipt, but
available.not receipt of other antimicrobials, is associated with
We found that VRE-colonized patients were presentVRE [3, 20]. However, in agreement with our findings,
in all seven outpatient units studied. Since stool or rectalmany studies have found that receipt of a variety of
cultures are rarely performed routinely at outpatient di-antimicrobials is associated with VRE [4, 5, 8, 19, 25].
alysis centers, VRE colonization in patients often will beBroad-spectrum antimicrobials, especially those with ac-
unknown to staff members. Therefore, careful infectiontivity against anaerobes, are most likely to be associated
control precautions should be practiced during care of
with VRE [26]. Our study did not have sufficient power all patients to prevent transmission. CDC recommends
to determine the independent effect of various antimicro- private rooms, disposable gloves, and gowns for care of
bials, but our results are most consistent with higher VRE hospitalized patients with VRE [28]. However, similar
prevalence in patients who received either vancomycin recommendations have not been made for outpatient
or other intravenously administered antimicrobials. It dialysis units [29, 30]. This is based partially on the as-
has been hypothesized that antimicrobial agents them- sumption that, in the dialysis unit, infection control pre-
selves do not cause vancomycin resistance; however, cautions will be followed for all patients (that is, gloves
once resistant organisms have spread to a given patient, will be worn for all touching of patients, gloves will
antimicrobials select for vancomycin-resistant strains, be removed and hands washed between patients, and
allowing them to increase in number [26]. surfaces at the dialysis station will be wiped with a disin-
Hospitalization has been associated previously with fectant between patients). Such precautions were origi-
VRE in ESRD patients [18]. Our analysis showed that nally recommended for hemodialysis units in 1977 to
hospitalization was significantly associated with VRE in prevent spread of the hepatitis B virus [31], but, with
univariate analysis, but after controlling for antimicro- the increasing prevalence of antimicrobial-resistant or-
bial use in a multivariate model, hospitalization was of ganisms, careful adherence to these precautions remains
only borderline statistical significance (P  0.12). critical. In addition to the use of general infection control
Transmission of VRE within a healthcare facility may measures, practices designed to prevent infections aris-
be inferred if a single genetic pattern is found among ing from hemodialysis catheters and implanted accesses
VRE isolates from the facility [27]. Evaluation of possi- should be followed [32, 33].
ble clustering of genetic types within the dialysis centers Judicious antimicrobial use, especially of vancomycin, is
in our study was hampered by the small numbers of recommended to limit selection for vancomycin-resistant
isolates available for testing. At four of five centers hav- strains [34]. Two recent studies suggest that cefazolin, a
ing 2 VRE isolates, no clusters were found. At one first-generation cephalosporin, could be substituted for
center (center F), there were two clusters of three and vancomycin where a -lactam susceptible organism is
identified, or where infection with a -lactam-resistanttwo isolates each, and three additional isolates that were
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Wayne, PA, National Committee for Clinical Laboratory Standards,organism is unlikely [35, 36]. Antimicrobial use and con-
1995
trol policies have been useful in limiting inappropriate 16. Tenover F, Arbeit R, Goering R, et al: Interpreting chromosomal
DNA restriction patterns produced by pulsed-field gel electropho-use of antimicrobials in hospitals [37, 38] and may be
resis: Criteria for bacterial strain typing. J Clin Microbiol 33:2233–useful in outpatient dialysis centers as well. Because of
2239, 1995
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